Please note that the ANZCTR website will be unavailable from 12am until 6am (AEST) on Sunday 22nd September 2019. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03631199




Registration number
NCT03631199
Ethics application status
Date submitted
6/08/2018
Date registered
15/08/2018
Date last updated
11/09/2019

Titles & IDs
Public title
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
Scientific title
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Secondary ID [1] 0 0
2018-001547-32
Secondary ID [2] 0 0
CACZ885U2301
Universal Trial Number (UTN)
Trial acronym
CANOPY-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - canakinumab
Treatment: Drugs - canakinumab matching placebo
Treatment: Drugs - pembrolizumab
Treatment: Drugs - carboplatin
Treatment: Drugs - cisplatin
Treatment: Drugs - paclitaxel
Treatment: Drugs - nab-paclitaxel
Treatment: Drugs - pemetrexed

Experimental: canakinumab - canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy

Other: canakinumab matching-placebo - canakinumab matching-placebo in combination with pembrolizumab and platinum-based doublet chemotherapy


Treatment: Drugs: canakinumab
canakinumab every 3 weeks (squamous and non-squamous)

Treatment: Drugs: canakinumab matching placebo
canakinumab placebo every 3 weeks (squamous and non-squamous)

Treatment: Drugs: pembrolizumab
200 mg every 3 weeks (squamous and non-squamous)

Treatment: Drugs: carboplatin
AUC 5 mg/mL*min every 3 weeks (non-squamous) or AUC 6 mg/mL*min (squamous)

Treatment: Drugs: cisplatin
75 mg/m2 every 3 weeks (non-squamous)

Treatment: Drugs: paclitaxel
200 mg/m2 every 3 weeks (squamous)

Treatment: Drugs: nab-paclitaxel
100 mg/m2 every 3 weeks (squamous)

Treatment: Drugs: pemetrexed
500 mg/m2 every 3 weeks (non-squamous)

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety run-in part: Incidence of dose limiting toxicities (DLTs) - Incidence of DLTs assessed among at least 6 evaluable subjects during the first 42 days of study treatment
Timepoint [1] 0 0
6 months from start of safety run-in part
Primary outcome [2] 0 0
Double-blind, randomized, placebo-controlled part: Progression free survival (PFS) per investigator assessment using RECIST v1.1 - Progression free survival is defined as the time from randomization to the date of the first documented radiological progression using RECIST 1.1(Response evaluation criteria in solid tumor) or death due to any cause
Timepoint [2] 0 0
18 months from start of randomization part
Primary outcome [3] 0 0
Double-blind, randomized, placebo-controlled part: Overall survival (OS) per investigator assessment using RECIST v1.1 - Overall survival is defined as the time from date of randomization to date of death due to any cause
Timepoint [3] 0 0
38 months from start of randomization part
Secondary outcome [1] 0 0
Safety run-in part: Overall response rate (ORR) per investigator assessment using RECIST v1.1 - ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1
Timepoint [1] 0 0
Baseline, every 6 weeks (for the first 12 weeks), then every 9 weeks (for the next 21 weeks) and every 12 weeks thereafter until progression per investigator assessment and up to 6 months
Secondary outcome [2] 0 0
Double-blind, randomized, placebo-controlled part : Overall response rate (ORR) per investigator assessment using RECIST v1.1 - ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1
Timepoint [2] 0 0
Baseline, every 6 weeks (for the first 12 weeks), then every 9 weeks (for the next 21 weeks) and every 12 weeks thereafter until progression per investigator assessment and up to 18 months
Secondary outcome [3] 0 0
Safety run-in part: Disease control rate (DCR) per investigator assessment using RECIST v1.1 - Disease control rate is defined as the proportion of patients with complete response (CR) or partial response (PR) or subjects with stable disease (SD) as per investigator assessment according to RECIST 1.1 criteria
Timepoint [3] 0 0
Baseline, every 6 weeks (for the first 12 weeks), then every 9 weeks (for the next 21 weeks) and every 12 weeks thereafter until progression per investigator assessment and up to 6 months
Secondary outcome [4] 0 0
Double-blind, randomized, placebo-controlled part : Disease control rate (DCR) per investigator assessment using RECIST v1.1 - Disease control rate is defined as the proportion of patients with complete response (CR) or partial response (PR) or subjects with stable disease (SD) as per investigator assessment according to RECIST 1.1 criteria
Timepoint [4] 0 0
Baseline, every 6 weeks (for the first 12 weeks), then every 9 weeks (for the next 21 weeks) and every 12 weeks thereafter until progression per investigator assessment and up to 18 months
Secondary outcome [5] 0 0
Safety run-in part: Duration of response (DOR) per investigator assessment using RECIST v1.1 - Duration of response is defined as the time from first documented response of CR or PR to date of first documented progression or death due to any cause, according to RECIST 1.1 criteria
Timepoint [5] 0 0
Baseline, every 6 weeks (for the first 12 weeks), then every 9 weeks (for the next 21 weeks) and every 12 weeks thereafter until progression per investigator assessment and up to 6 months
Secondary outcome [6] 0 0
Double-blind, randomized, placebo-controlled part : Duration of response (DOR) per investigator assessment using RECIST v1.1 - Duration of response is defined as the time from first documented response of CR or PR to date of first documented progression or death, according to RECIST 1.1 criteria
Timepoint [6] 0 0
Baseline, every 6 weeks (for the first 12 weeks), then every 9 weeks (for the next 21 weeks) and every 12 weeks thereafter until progression per investigator assessment and up to 18 months
Secondary outcome [7] 0 0
Double-blind, randomized, placebo-controlled part only: Time to response (TTR) per investigator assessment using RECIST v1.1 - Time to response (TTR) is defined as duration of time between the date of randomization and the date of first documented response of either CR or PR, according to RECIST 1.1 criteria
Timepoint [7] 0 0
Baseline, every 6 weeks (for the first 12 weeks), then every 9 weeks (for the next 21 weeks) and every 12 weeks thereafter until progression per investigator assessment and up to 18 months
Secondary outcome [8] 0 0
Safety run-in part: Antidrug antibodies (ADA) of canakinumab
Timepoint [8] 0 0
Predose (0 h) on Day 1 of Cycles 1, 4, 8, 12, 16 (Cycle length =21 days), at end of treatment & then at 26, 78 and 130 days after last dose
Secondary outcome [9] 0 0
Double-blind, randomized, placebo-controlled part : Antidrug antibodies (ADA) of canakinumab
Timepoint [9] 0 0
Predose (0 h) on Day 1 of Cycles 1, 4, 8, 12, 16 (Cycle length =21 days), at end of treatment & then at 26, 78 and 130 days after last dose
Secondary outcome [10] 0 0
Safety run-in part: Antidrug antibodies (ADA) of pembrolizumab
Timepoint [10] 0 0
Predose (0 h) on Day 1 of Cycles 1, 2, 4, 8, 12, 16 (Cycle length =21 days), at end of treatment & then at 26 days after last dose
Secondary outcome [11] 0 0
Double-blind, randomized, placebo-controlled part : Antidrug antibodies (ADA) of pembrolizumab
Timepoint [11] 0 0
Predose (0 h) on Day 1 of Cycles 1, 2, 4, 8, 12, 16 (Cycle length =21 days), at end of treatment & then at 26 days after last dose
Secondary outcome [12] 0 0
Safety run-in part: Serum canakinumab concentration
Timepoint [12] 0 0
Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on D2, D8, D15 of Cycle 1, Post dose on C5D8, at end of treatment & then at 26, 78 and 130 days after last dose (Cycle length =21 days)
Secondary outcome [13] 0 0
Double-blind, randomized, placebo-controlled part : Serum canakinumab concentration
Timepoint [13] 0 0
Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on D2, D8, D15 of Cycle 1, Postdose on C5D8, at end of treatment & then at 26, 78 and 130 days after last dose (Cycle length =21 days)
Secondary outcome [14] 0 0
Safety run-in part: Serum pembrolizumab concentration
Timepoint [14] 0 0
Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on D2, D8, D15 of Cycle 1, at end of treatment & then at 26 days after last dose (Cycle length =21 days)
Secondary outcome [15] 0 0
Double-blind, randomized, placebo-controlled part : Serum pembrolizumab concentration
Timepoint [15] 0 0
Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on D2, D8, D15 of Cycle 1, at end of treatment & then at 26 days after last dose (Cycle length =21 days)
Secondary outcome [16] 0 0
Safety run-in part: Plasma pemetrexed concentration
Timepoint [16] 0 0
Pre (0 h) and end of infusion on Cy 1 and 2, 1, 4, 8 h post infusion on Cy 1, 1, 2, 4, 8h post infusion on Cy 2 (Cy length =21 days)
Secondary outcome [17] 0 0
Double-blind, randomized, placebo-controlled part : : Plasma pemetrexed concentration
Timepoint [17] 0 0
Pre (0 h) and end of infusion of Cy 1 and 2, 1, 4, 8 h post infusion on Cy 1, 1, 2, 4, 8 h post infusion on Cy 2 (Cy length =21 days)
Secondary outcome [18] 0 0
Safety run-in part: Plasma cisplatin concentration
Timepoint [18] 0 0
Pre (0 h) and end of infusion on Cy 1 and 2, 2, 4, 8 h post infusion on Cy 1, 1.5, 2, 4, 8 h post infusion on Cy 2 (Cy length =21 days)
Secondary outcome [19] 0 0
Double-blind, randomized, placebo-controlled part: Plasma cisplatin concentration
Timepoint [19] 0 0
Pre (0 h) and end of infusion on Cy 1 and 2, 2, 4, 8 h post infusion on Cy 1, 1.5, 2, 4, 8 h post infusion on Cy 2 (Cy length = 21 days)
Secondary outcome [20] 0 0
Safety run-in part: Plasma carboplatin concentration
Timepoint [20] 0 0
Pre (0 h), end of infusion, 1, 2, 4, 8 h post infusion on Cycles 1 and 2 (Cycle length =21 days)
Secondary outcome [21] 0 0
Double-blind, randomized, placebo-controlled part: Plasma carboplatin concentration
Timepoint [21] 0 0
Pre (0 h), end of infusion, 1, 2, 4, 8 h post infusion on Cycles 1 and 2 (Cycle length =21 days)
Secondary outcome [22] 0 0
Safety run-in part: Plasma paclitaxel concentration
Timepoint [22] 0 0
Pre (0 h) and end of infusion on Cy 1 and 2, 4, 8, 12 h post infusion on Cycles 1, 4, 6, 8, 12 h post infusion on Cycle 2 (Cycle length =21 days)
Secondary outcome [23] 0 0
Double-blind, randomized, placebo-controlled part: Plasma paclitaxel concentration
Timepoint [23] 0 0
Pre (0 h) and end of infusion on Cy 1 and 2, 4, 8, 12 h post infusion on Cy 1, 4, 6, 8, 12 h post infusion on Cy 2 (Cy length =21 days)
Secondary outcome [24] 0 0
Double-blind, randomized, placebo-controlled part: Plasma nab-paclitaxel concentration
Timepoint [24] 0 0
Pre (0 h) and end of infusion on Cy 1 and 2, 4, 8, 12 h post infusion on Cy 1, 4, 6, 8, 12 h post infusion on Cy 2 (Cy length =21 days)
Secondary outcome [25] 0 0
Double-blind, randomized, placebo-controlled part only :Time to definitive 10 point deterioration symptom scores of pain, cough and dyspnea per QLQ-LC13 questionnaire - To assess the effect of canakinumab vs placebo on time to onset or deterioration of lung cancer specific symptoms
Timepoint [25] 0 0
Baseline and at day 1 of every visit (with dosing or not) until end of treatment, before each tumor assessments and 2 times (7 days and 28 days) after disease progression and up to 18 months
Secondary outcome [26] 0 0
Double-blind, randomized, placebo-controlled part only: Time to definitive deterioration in global health status/QoL, shortness of breath and pain per QLQ-C30 questionnaire - To assess the effect of canakinumab vs placebo on time to onset or deterioration of lung cancer specific symptoms
Timepoint [26] 0 0
Baseline and at day 1 of every visit (with dosing or not) until end of treatment, before each tumor assessments and 2 times (7 days and 28 days) after disease progression and up to 18 months
Secondary outcome [27] 0 0
Double-blind, randomized, placebo-controlled part only: change from baseline in score as per the EQ-5D-5L questionnaire - To assess the effect of canakinumab versus placebo on patient reported outcomes ((PROs) - patient's health related quality of life)
Timepoint [27] 0 0
Baseline and at day 1 of every visit (with dosing or not) until end of treatment, before each tumor assessments and 2 times (7 days and 28 days) after disease progression and up to 18 months

Eligibility
Key inclusion criteria
Key inclusion criteria:

- Histologically confirmed locally advanced stage IIIB or stage IV NSCLC for treatment
in the first-line setting

- Known PD-L1 status determined by a Novartis designated central laboratory. A newly
obtained tissue biopsy or an archival biopsy (block or slides) is required for PD-L1
determination (PD-L1 IHC 22C3 pharmDx assay), prior to study randomization. Note: For
the safety run-in part, known PD-L1 status is not required.

- Eastern Cooperative oncology group (ECOG) performance status of 0 or 1.

- At least 1 measurable lesion by RECIST 1.1

Key exclusion criteria:

- Previous immunotherapy (e.g. anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody,
or any other antibody or drug specifically targeting T-cell co-stimulation or immune
checkpoint pathways).

- Prior treatment with canakinumab or drugs of a similar mechanism of action (IL-1ß
inhibitor).

- Subjects with epidermal growth factor receptor (EGFR) sensitizing mutations
(identified in exons 19, 20, or 21), and/or ALK rearrangement by locally approved
laboratory testing.

- Previously untreated or symptomatic central nervous system (CNS) metastases or
lepto-meningeal disease.

- Subject with suspected or proven immune-compromised state or infections.

- Subject has prior to starting study drug: received live vaccination =3 months, had
major surgery =4 weeks prior to starting study drug, has thoracic radiotherapy: lung
fields = 4 weeks, other anatomic sites = 2 weeks, palliative radiotherapy for bone
lesions = 2 weeks.

Other protocol-defined inclusion/exclusion criteria may apply.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Westmead
Recruitment hospital [2] 0 0
Novartis Investigative Site - Wooloongabba
Recruitment hospital [3] 0 0
Novartis Investigative Site - Melbourne
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
4102 - Wooloongabba
Recruitment postcode(s) [3] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
District of Columbia
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Mississippi
Country [6] 0 0
United States of America
State/province [6] 0 0
Washington
Country [7] 0 0
Argentina
State/province [7] 0 0
Buenos Aires
Country [8] 0 0
Austria
State/province [8] 0 0
Linz
Country [9] 0 0
Austria
State/province [9] 0 0
Salzburg
Country [10] 0 0
Canada
State/province [10] 0 0
Alberta
Country [11] 0 0
Canada
State/province [11] 0 0
Ontario
Country [12] 0 0
Czechia
State/province [12] 0 0
Czech Republic
Country [13] 0 0
Czechia
State/province [13] 0 0
Brno - Bohunice
Country [14] 0 0
Czechia
State/province [14] 0 0
Ostrava Vitkovice
Country [15] 0 0
France
State/province [15] 0 0
Bouches Du Rhone
Country [16] 0 0
France
State/province [16] 0 0
Lyon Cedex
Country [17] 0 0
France
State/province [17] 0 0
Montpellier
Country [18] 0 0
France
State/province [18] 0 0
Paris
Country [19] 0 0
France
State/province [19] 0 0
Saint Herblain
Country [20] 0 0
Germany
State/province [20] 0 0
Berlin
Country [21] 0 0
Germany
State/province [21] 0 0
Dresden
Country [22] 0 0
Germany
State/province [22] 0 0
Essen
Country [23] 0 0
Germany
State/province [23] 0 0
Georgsmarienhuette
Country [24] 0 0
Germany
State/province [24] 0 0
Gerlingen
Country [25] 0 0
Germany
State/province [25] 0 0
Gottingen
Country [26] 0 0
Germany
State/province [26] 0 0
Halle (Saale)
Country [27] 0 0
Germany
State/province [27] 0 0
Heidelberg
Country [28] 0 0
Germany
State/province [28] 0 0
Koeln
Country [29] 0 0
Germany
State/province [29] 0 0
Leipzig
Country [30] 0 0
Germany
State/province [30] 0 0
Muenchen
Country [31] 0 0
Hong Kong
State/province [31] 0 0
Kowloon
Country [32] 0 0
Iceland
State/province [32] 0 0
Reykjavik
Country [33] 0 0
India
State/province [33] 0 0
Andhra Pradesh
Country [34] 0 0
India
State/province [34] 0 0
Maharashtra
Country [35] 0 0
India
State/province [35] 0 0
Rajasthan
Country [36] 0 0
India
State/province [36] 0 0
Telangana
Country [37] 0 0
India
State/province [37] 0 0
West Bengal
Country [38] 0 0
Italy
State/province [38] 0 0
CT
Country [39] 0 0
Italy
State/province [39] 0 0
MI
Country [40] 0 0
Italy
State/province [40] 0 0
MO
Country [41] 0 0
Italy
State/province [41] 0 0
PR
Country [42] 0 0
Italy
State/province [42] 0 0
TO
Country [43] 0 0
Italy
State/province [43] 0 0
Perugia
Country [44] 0 0
Japan
State/province [44] 0 0
Aichi
Country [45] 0 0
Japan
State/province [45] 0 0
Ehime
Country [46] 0 0
Japan
State/province [46] 0 0
Hokkaido
Country [47] 0 0
Japan
State/province [47] 0 0
Hyogo
Country [48] 0 0
Japan
State/province [48] 0 0
Kanagawa
Country [49] 0 0
Japan
State/province [49] 0 0
Osaka
Country [50] 0 0
Japan
State/province [50] 0 0
Shizuoka
Country [51] 0 0
Japan
State/province [51] 0 0
Tokyo
Country [52] 0 0
Japan
State/province [52] 0 0
Yamaguchi
Country [53] 0 0
Korea, Republic of
State/province [53] 0 0
Korea
Country [54] 0 0
Korea, Republic of
State/province [54] 0 0
Seocho Gu
Country [55] 0 0
Korea, Republic of
State/province [55] 0 0
Seoul
Country [56] 0 0
Lebanon
State/province [56] 0 0
Beirut
Country [57] 0 0
Lebanon
State/province [57] 0 0
Saida
Country [58] 0 0
Malaysia
State/province [58] 0 0
Pahang
Country [59] 0 0
Malaysia
State/province [59] 0 0
Sarawak
Country [60] 0 0
Malaysia
State/province [60] 0 0
Wilayah Persekutuan
Country [61] 0 0
Malaysia
State/province [61] 0 0
Kuala Lumpur
Country [62] 0 0
Netherlands
State/province [62] 0 0
Groningen
Country [63] 0 0
Philippines
State/province [63] 0 0
Makati City
Country [64] 0 0
Philippines
State/province [64] 0 0
San Juan City
Country [65] 0 0
Poland
State/province [65] 0 0
Gliwice
Country [66] 0 0
Poland
State/province [66] 0 0
Olsztyn
Country [67] 0 0
Poland
State/province [67] 0 0
Poznan
Country [68] 0 0
Poland
State/province [68] 0 0
Tomaszw Mazowiecki
Country [69] 0 0
Singapore
State/province [69] 0 0
Singapore
Country [70] 0 0
Slovakia
State/province [70] 0 0
Bratislava
Country [71] 0 0
Slovakia
State/province [71] 0 0
Poprad
Country [72] 0 0
Spain
State/province [72] 0 0
Andalucia
Country [73] 0 0
Spain
State/province [73] 0 0
Catalunya
Country [74] 0 0
Spain
State/province [74] 0 0
Comunidad Valenciana
Country [75] 0 0
Spain
State/province [75] 0 0
Las Palmas De Gran Canaria
Country [76] 0 0
Spain
State/province [76] 0 0
Pais Vasco
Country [77] 0 0
Spain
State/province [77] 0 0
Madrid
Country [78] 0 0
Spain
State/province [78] 0 0
Zaragoza
Country [79] 0 0
Switzerland
State/province [79] 0 0
Basel
Country [80] 0 0
Taiwan
State/province [80] 0 0
Kaohsiung City
Country [81] 0 0
Taiwan
State/province [81] 0 0
Tainan
Country [82] 0 0
Taiwan
State/province [82] 0 0
Taipei
Country [83] 0 0
Taiwan
State/province [83] 0 0
Taoyuan
Country [84] 0 0
Thailand
State/province [84] 0 0
Hat Yai
Country [85] 0 0
Thailand
State/province [85] 0 0
THA
Country [86] 0 0
Thailand
State/province [86] 0 0
Bangkok
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Plymouth
Country [88] 0 0
Vietnam
State/province [88] 0 0
Hanoi

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or
without canakinumab in previously untreated locally advanced or metastatic non-squamous and
squamous NSCLC subjects.

The study will assess primarily the safety and tolerability (safety run-in part) of
pembrolizumab plus platinum-based doublet chemotherapy with canakinumab and then the efficacy
(double-blind, randomized, placebo controlled part) of pembrolizumab plus platinum-based
doublet chemotherapy with or without canakinumab.
Trial website
https://clinicaltrials.gov/show/NCT03631199
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
1-888-669-6682
Fax 0 0
Email 0 0
novartis.email@novartis.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03631199